Identifying cell populations in PDAC with scRNA-seq. We first processed fresh primary PDAC tumors from two untreated Single-cell RNA sequencing (scRNA-seq) enables the systematic identification of cell populations in a tissue, but characterizing their spatial organization remains challenging. We combine a microarray-based spatial transcriptomics method that reveals spatial patterns of gene expression using an array of spots, each capturing the transcriptomes of multiple adjacent cells, with scRNA-Seq generated from the same sample. To annotate the precise cellular composition of distinct tissue regions, we introduce a method for multimodal intersection analysis. Applying multimodal intersection analysis to primary pancreatic tumors, we find that subpopulations of ductal cells, macrophages, dendritic cells and cancer cells have spatially restricted enrichments, as well as distinct coenrichments with other cell types. Furthermore, we identify colocalization of inflammatory fibroblasts and cancer cells expressing a stress-response gene module. Our approach for mapping the architecture of scRNA-seq-defined subpopulations can be applied to reveal the interactions inherent to complex tissues.
R ecent technological advances have enabled a view into cancer at unprecedented molecular resolution 1 . scRNA-seq has emerged as a powerful tool for the unbiased and systematic characterization of the cells present in a given tissue 2, 3 . Indeed, the application of scRNA-seq to patient tumors has uncovered multiple cellular subpopulations and has highlighted intercellular cross-talk within the tumor microenvironment [4] [5] [6] [7] [8] [9] [10] . In particular, over the past 5 yr many independent reports have found evidence for intratumoral transcriptional heterogeneity among cancer cells [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . While these results clearly highlight the power of scRNA-seq, tissue dissociation before sequencing leads to the loss of spatial information, thus limiting our understanding of cellular interactions and organization in the tumor microenvironment.
Methods providing spatially resolved transcriptomic profiling [20] [21] [22] [23] [24] have also been introduced and are complementary to scRNA-seq. To resolve the cell type spatial composition of tissues, the integration of in situ hybridization (ISH) gene expression atlases with scRNA-seq data has been useful to map rare subpopulations and cell types using a small subset of genes 25, 26 . Such ISH atlases used for tissue with defined morphology do not exist for solid tumors, however, which have variable tissue architecture and gene expression patterns. Moreover, the throughput of ISH methods remains limited to a subset of the transcriptome, thus preventing comprehensive expression analysis in a single experiment.
The recently developed spatial transcriptomics (ST) method 27 overcomes the throughput limitation of ISH methods, allowing for unbiased mapping of transcripts over entire tissue sections using spatially barcoded oligo-deoxythymidine microarrays (Fig. 1a ). ST has already been used to study the mouse olfactory bulb 27 , breast cancer 27 , melanoma 28 , prostate cancer 29 , gingival tissue 30 , adult human heart tissue 31 , mouse and human spinal cord tissue 32 , as well as model plant species 33 . Similar to other previously reported spatially resolved transcriptomic tools 20, 34, 35 , however, a main limitation of ST is its lack of cellular resolution; each spot captures the transcriptomes of 10-200 cells depending on the tissue context 36 .
While scRNA-seq and ST data each have limitations, we reasoned that these could be overcome by an integration of the two data modalities to enable comprehensive and unbiased tissue analysis. Here, we present an integration of scRNA-seq with the ST method to study pancreatic ductal adenocarcinoma (PDAC). In this approach, a tumor is first divided and a single-cell suspension is generated from one portion and processed for scRNA-seq to identify the cell populations present in the tissue. From the remaining tissue, cryosections are processed using the ST method to provide an unbiased map of expressed transcripts across the tissue. We then integrate these two datasets by introducing multimodal intersection analysis (MIA). Our approach infers the enrichment of specific cell types in a given tissue region by computing the degree of overlap between genes specifically mapped to that region and the cell type-specific genes identified by the scRNA-seq data. Studying primary PDAC tumors from different patients, we identified enrichments of specific cell types and subpopulations across spatially restricted regions of the tissue. Our approach for combining these two complementary and powerful technologies is easily scalable to any architecturally complex tissue and has the potential to provide meaningful biological insight across a range of fields.
patients-PDAC-A and PDAC-B-for parallel scRNA-seq and ST analysis ( Fig. 1a and see Methods). The scRNA-seq data consisted of cells with approximately 2,500-3,300 unique molecular identifiers (UMIs) and approximately 1,400-1,700 uniquely expressed genes per cell ( Supplementary Fig. 1 ). To infer cell type identities, we used a recursive hierarchical clustering scheme (see Methods) that applies our recently developed k-nearest neighbors (KNN) smoothing algorithm 37 to reduce the noise inherent to scRNA-seq data 38 . We identified 15 and 11 distinct populations in the PDAC-A and PDAC-B tumors, respectively, providing an in-depth perspective of the PDAC tumor microenvironment (Fig. 1b) . The gene expression profiles of shared cell types showed strong correlation between the patient samples, validating our annotation of clusters across samples ( Fig. 1c) .
To distinguish the PDAC cancer cells from the nonmalignant ductal cells, we used scRNA-seq-based copy number variation (CNV) analysis (as performed previously 4 ; see Methods). For each identified cell type, we inferred chromosomal amplifications and deletions (with the cells of other clusters as the background) and detected two clusters in PDAC-A and one cluster in PDAC-B that displayed aberrant CNV profiles ( Fig. 1d,e ). Notably, the deletion along chromosome 6 in both samples and the amplification on chromosome 7 in the PDAC-B profile are consistent with the most common chromosomal abnormalities seen in PDAC from cytogenetic Surgically resected PDAC tumors are split and processed in parallel for scrNA-seq and ST. After clustering, the cell type of each cluster is inferred according to specifically expressed genes. Cryosections of the remaining tissue were used for ST analysis in which each spot captures the transcriptomes of the cells at a specific location in the tissue. Applying our multimodal intersection analysis (MIA) across the two datasets reveals the spatial distribution of the cell populations and subpopulations. b, t-SNE projection of 1,926 cells from the PDAC-A tumor (left panel) and 1,733 cells from PDAC-B (right panel). Clusters are colored and labeled according to their inferred cell type identities. c, Correspondence between PDAC-A and PDAC-B cell types computed by Pearson's correlation on the average cell type transcriptomes of shared cell types (see Methods). d,e, CNV profiles inferred from scrNA-seq on PDAC-A (d) and PDAC-B (e). red and blue indicate chromosomal amplifications and deletions, respectively. f, Double immunofluorescence staining of markers for cancer cell subpopulations (n = 2). Top panel, double staining of TM4SF1 (cancer cluster 1) and S100A4 (cancer cluster 2) in PDAC-A FFPE tissue. Note the mutual exclusion of TM4SF1 and S100A4 signals. Middle, KrT19 and TM4SF1 staining in PDAC-B tissue. Bottom, KrT19 and S100A4 staining in PDAC-B tissue. Note colocalization of KrT19 and TM4SF1 signals, but a lack of S100A4 signal in PDAC-B as expected. Scale bars, 100 µm. Chr, chromosome; DC, dendritic cell; ID, spatial barcode identification; NK, natural killer; pDC, plasmacytoid dendritic cell; rBC, red blood cell. data 39 . As a negative control, we removed a random subset of ductal cells from the background and inferred the relative CNV profiles of these cells. We found that while these profiles are noisy, they do not provide evidence for aberrant CNVs ( Supplementary Fig. 2a ). The CNV profiles of the PDAC-B cancer cells do show a degree of variation, perhaps reflecting minor heterogeneities within a single clone since transcriptionally they form a single cluster of malignant cells (Fig. 1b) .
The two PDAC-A cancer clusters-cancer clusters 1 and 2exhibited high expression of TM4SF1 (cluster 1) or S100A4 (cluster 2) while the PDAC-B cancer cluster was high in TM4SF1 expression ( Supplementary Fig. 2b ), suggesting similarity between PDAC-A cancer cluster 1 and the PDAC-B cancer cluster. To further validate whether the TM4SF1-and S100A4-expressing populations identified in the scRNA-seq data represent cancer cell populations, we performed double immunofluorescence staining of TM4SF1 and S100A4 on formalin-fixed paraffin embedded (FFPE) tissue originating from the same patients ( Fig. 1f and Supplementary Fig. 2c,d ). We found TM4SF1 and S100A4 signals in malignant PDAC-A ducts as identified by morphology ( Supplementary Fig. 2c ,d, top panels), but not in nonmalignant ducts (bottom panels). Consistent with the transcriptomic data, the PDAC-A cancer cells displayed mutually exclusive staining for TM4SF1 and S100A4 ( Fig. 1f , top). When we double-stained PDAC-B tissue for KRT19-a marker for both malignant and nonmalignant pancreatic ductal cells-and TM4SF1, or KRT19 and S100A4, we found colocalization of the KRT19 and TM4SF1 signals ( Fig. 1f , middle) but no colocalization of the KRT19 and S100A4 signals (Fig. 1f, bottom) . This validates expression of TM4SF1 and not S100A4 in the malignant cells of PDAC-B. Taken together with the distinct CNV profiles for the cancer clusters, we confirm the presence of genetically and transcriptionally distinct cancer cell populations in the PDAC-A sample.
ST of PDAC tissue. To generate unbiased transcriptomic maps of the tissue sections, we mounted cryosections of the two unfixed PDAC tissues originating from the same tumor sample onto the spatially barcoded ST microarray slides (see Methods). After hematoxylin and eosin (H&E) staining and brightfield imaging, we annotated the slide for distinct histological features ( Fig. 2a,b ). In the PDAC-A tumor section, we defined four main regions: cancer cells and desmoplasia, nonmalignant duct epithelium, stroma and normal acini-rich pancreatic tissue ( Fig. 2a and Supplementary  Fig. 3a-d ). The PDAC-B tissue section ( Fig. 2b ) did not appear to contain normal pancreatic tissue; however, we noted the presence of interstitial space adjacent to the cancer ( Supplementary Fig. 3e ,f).
The samples were then processed for ST analysis, including complementary DNA synthesis, amplification by in vitro transcription, library construction and sequencing 19 . We demultiplexed the sequenced reads and identified their spatial location within the tissue using the ST location-specific barcodes of the array. We used the H&E images to estimate that each ST spot captured approximately 20-70 cells ( Supplementary Fig. 4 ). We expect these numbers to be highly variable depending on the tissue histology 36 . For example, highly fibrotic regions with dense connective tissue (and therefore lower cellular content) may have low cell number per spot compared with regions with high cellular density such as the acinus of the pancreas ( Supplementary Fig. 4 ). We detected approximately 2,400 UMIs and approximately 1,000 unique genes per spot for both ST datasets ( Supplementary Fig. 5a -f). Other published works using the ST method (particularly on human tissue) report similar statistics for the average number of UMIs per spot (Supplementary Table 1 ). In both sample datasets, we found that the spatial expression of many variably expressed genes (see Methods) matched the annotated histological regions ( Fig. 2c,d) .
We classified the ST data into regions by first performing principal component analysis (PCA) on the most variably expressed genes across all ST spots ( Supplementary Fig. 5g ,h and see Methods). After clustering the spots of each ST array based on the principal component scores (see Methods), we found that the resulting clusters were consistent with the independent histological annotations ( Fig. 2e ,f and Supplementary Fig. 5g ,h), supporting the ability to identify distinct spatial regions within a section based on ST gene expression alone.
Multimodal intersection analysis (MIA).
To integrate the scRNAseq and ST datasets, we developed MIA. This analysis proceeds by first delineating sets of cell type-specific and tissue region-specific genes and then determining whether their overlap is higher (enrichment) or lower (depletion) than expected by chance. In the scRNAseq data, we defined the gene sets by identifying for each cell type those genes whose expression is statistically higher in the cells annotated to that cell type in comparison with expression in the remaining cells (P < 10 −5 , two-tailed Student's t-test; see Methods). For the ST data, we then identified genes with significantly higher expression in each spatial region relative to the others (P < 0.01, two-tailed Student's t-test).
With the gene sets extracted across the scRNA-seq and ST modalities, MIA next computes the overlap between each pair of cell type-specific and region-specific gene sets and performs a hypergeometric test to assess significant enrichment or depletion. As an example, we found that the fibroblast-specific genes in PDAC-A overlapped significantly with the set of genes specific to the cancer region of the ST data ( Fig. 2g ; P < 10 −10 ). Extending this analysis to all pairs of cell types and tumor regions produces an 'MIA map' . Thus, while the scRNA-seq data led to identification of fibroblasts, MIA further revealed that these were enriched in the cancer region, as opposed to the stromal region, suggesting that the fibroblasts captured by scRNA-seq represent activated fibroblasts 40 (Fig. 2h ). As expected, we found that the duct epithelium region was mainly enriched with ductal cells, while the pancreatic tissue was enriched with acinar cells and endocrine cells (P < 10 −10 , for all specified enrichments). Similarly, a MIA map was generated for the PDAC-B sample ( Fig. 2i ). Testing a range of thresholds for marker gene selection for both modalities, we found that the MIA approach is robust at identifying enrichments and depletions of cell types across spatial regions ( Supplementary Fig. 5i ,j). To assess the robustness to the number of genes required for MIA maps, we found that when the number of detected genes in the cancer region was downsampled below 100 genes, an enrichment with fibroblastspecific genes dropped below significance (P > 0.05; Supplementary  Fig. 5k ). These results support a broad utility of MIA maps to provide spatial and functional annotations for the scRNA-seq-defined cell populations.
Identification and mapping of cell type subpopulations across tissue regions. One of the most useful aspects of scRNA-seq is its ability to reveal distinct subpopulations within cell types. We thus sought to characterize intra-population heterogeneity by identifying subpopulations within cell types and then applying MIA to query for spatially restricted mapping across the tissue. From both tumor samples, a majority of the scRNA-seq cells consisted of KRT19expressing ductal cells ( Fig. 1b and Supplementary Fig. 2b ), one of the two main constituent cell types of the pancreatic exocrine system 41 . We identified a total of four ductal subpopulations: a ductal population expressing APOL1 and hypoxia-response-related genes including ERO1A (ref. 42 ) and CA9 (ref. 43 ); a terminal ductal population expressing TFF1, TFF2 and TFF3 (ref. 44 ); a centroacinar ductal population expressing CRISP3 and CFTR (ref. 44 ); and antigen-presenting ductal cells expressing major histocompatibility complex (MHC) class II genes CD74, HLA-DPA1, HLA-DQA2, HLA-DRA, HLA-DRB1 and HLA-DRB5 and complement pathway components C1S, C4A, C4B, CFB and CFH ( Fig. 3a-d ). Although MHC class II molecules are primarily expressed on the surface of professional antigen-presenting cells (B-cells, macrophages, dendritic cells), epithelial cells in the liver, gastrointestinal and respiratory tracts are known to express MHC class II (refs. 45, 46 ). Because of their presence in the tumor, it is likely that these antigen-presenting ductal cells play a role in modulating the inflammatory response within the tumor microenvironment by promoting T-cell activation 45, 46 . Notably, past work studying pancreatic ductal cells at single-cell resolution reported the presence of terminal and centroacinar ductal subpopulations 44 , but did not detect populations displaying the particular antigen-presenting or APOL1-high/hypoxic gene signatures present in the PDAC tumor ductal cells described here. When we performed double immunofluorescence of archival FFPE patient tissue, we found colocalization of subpopulation markers with the duct marker KRT19, confirming the presence of these ductal cell subpopulations ( Fig. 3e-h and Supplementary Fig. 6 ).
As in our cell type analysis, we used marker genes specific to each ductal subpopulation to determine the enrichment of these ductal subpopulations across the tissue region using MIA. As expected, we found that all ductal subpopulations in PDAC-A were enriched in the duct region of the tissue. In contrast, only the hypoxic and terminal ductal cell populations were significantly enriched in the cancer region (P < 10 −4 ; Fig. 3i ). It is possible that the transcriptional phenotypes exhibited by these ductal cells reflect environmental signals from the surrounding tissue; that is, ductal cells in the cancer region may express hypoxia-response genes due to low oxygen content. Additionally, the hypoxic ductal cells appeared to be depleted in the pancreatic tissue (P < 10 −3 ; Fig. 3i ). In contrast, the ductal subpopulations in PDAC-B were all exclusively enriched in the ducts of the tissue (P < 10 −4 ; Fig. 3j ).
We also found that the PDAC-A macrophages comprised two subpopulations, one of which expressed IL1B corresponding to an The hypergeometric distribution is used to infer the significance of the intersection of genes specifically expressed in a given cell type (fibroblasts in this case) and genes specifically expressed in a given tissue region (cancer region). Applying this analysis systematically for all pairs of cell types and tissue regions allows for insight into the spatial distribution of the cell types in the tumor. The numbers of genes used in the calculation are shown. h, The PDAC-A MIA map of all scrNA-seq-identified cell types and ST-defined regions. Each element in the matrix is computed as described in g for all pairs of cell types and tissue regions using the same 19,738 background genes. The numbers of cell type-and tissue region-specific genes used in the calculation are shown. red indicates enrichment (significantly high overlap); blue indicates depletion (significantly low overlap). The bar on top indicates the regions delineated in e. i, The PDAC-B MIA map for the ST clusters identified in f. Matrix elements were computed as described in g and h. The bar on top indicates the regions delineated in f. inflammatory M1 state 47 , and the other resembling the M2 alternatively activated state based on its expression of CD163 and MS4A4A (ref. 48 ) ( Supplementary Fig. 7a ). When we tested for the enrichment of these macrophage subpopulations across the tissue with MIA, we found that they appeared to have opposite patterns of enrichment across the tissue ( Supplementary Fig. 7b ). The M2-like macrophages were most enriched in the ducts, consistent with their function as tissue resident macrophages, while the M1 macrophages were more enriched in the stroma and cancer regions, reflecting an inflammatory environment in these regions ( Supplementary Fig. 7b ). We also found two subpopulations of dendritic cells, A and B, with subpopulation B expressing higher levels of complement pathway genes and MHC class II ( Supplementary Fig. 7c ). Dendritic cell subpopulation A was most enriched in pancreatic tissue, while subpopulation B appeared most enriched in the ducts of the tissue ( Supplementary Fig. 7d ). Based on the MIA maps, it is likely that these subpopulations play unique roles in the tissue based on their differential localization.
PDAC-
Mapping distinct cancer populations across PDAC tissue sections. We found two cancer cell populations in the PDAC-A scRNAseq data that appeared to be both genetically and transcriptionally distinct ( Fig. 1b-e ). Although we found both cancer populations to be highly enriched in the corresponding ST cancer region (Fig. 2h) , we asked whether they colocalized with different cell types within this region. To address this question, we processed for ST analysis two additional tissue sections originating from different regions of the same PDAC-A tumor ( Supplementary Fig. 8a-d ). Our protocol ensures that the scRNA-seq data are representative of all ST sections: the tumor was first divided into three parts, then each of these was split between ST and scRNA-seq (see Methods). Comparing regions across PDAC-A replicates, we determined the overlap among the list of genes specific to the respective PDAC-A sample regions, and found significant overlap between the cancer and stromal regions across the ST datasets ( Supplementary Fig. 8e ). For the cancer-rich regions in each tissue section, we used hierarchical clustering to further divide the cancer-rich regions into transcriptionally coherent subregions ( Fig. 4a-c ). After defining sets of genes specific to each subregion, we again applied our MIA mapping approach to study the overlap between the gene sets associated with the subregions and the sets of genes defined for each cell type and subpopulation from the scRNA-seq data (Fig. 4d ). For example, in cancer subregion 2 of the PDAC-A-1 sample, we found enrichment of only the cancer cluster 1 subpopulation together with fibroblasts. Consistently across the three PDAC-A tissue sections, we observed an enrichment of fibroblasts in tissue regions with high enrichment of cancer cluster 1 but weak or no enrichment of cancer cluster 2 (Fig. 4d ). This pattern suggests that the cancer cluster 1 cells may illicit a particular stromal response in the tissue, or that the cancer cluster 2 cells are mutually exclusive with fibroblasts in the tissue.
Deconvolving cell state relationships in the tumor microenvironment.
Recent work on scRNA-seq data of cancer cells has revealed unique cell states in multiple cancer types, including in glioblastoma 4,11 , melanoma 6 , and head and neck cancer 17 . Since ST provides spatial information, we asked whether we could map cancer cell states to distinct spatial tissue regions and characterize their interactions with other cell types using our MIA approach. For this we generated a third PDAC scRNA-seq dataset ( Supplementary Fig. 9 ) and used the combined scRNA-seq datasets to define three gene expression modules among the PDAC cancer cells ( Fig. 5a and as hypoxia-response, oxidative phosphorylation and stress-response modules. In particular, the stress-response module was of interest to us as this has also been studied by our group and others 6, 17, 19 . Furthermore, several genes in this module have been implicated in the regulation of cell growth 49 and invasive phenotypes 50 , suggesting a role for this gene module in tumor progression.
To adapt MIA to study the stress-response cancer cell state, we identified the genes with expression associated in those spots with high expression of the stress module. We first distinguished two clusters of ST cancer spots based on high and low expression of the stress-response module ( Fig. 5b and see Methods) . Next, we identified the genes that are specifically expressed in this cancer subregion and intersected them with cell type-specific genes using MIA. Using this analysis workflow, we found enrichment with the inflammatory fibroblasts in the PDAC-A-1 ST (P = 0.0012; Fig. 5b and see Methods). Similarly, we found strong enrichment between the genes of the stress-module high spots and the inflammatory fibroblasts in nine other ST arrays: two additional PDAC-A samples, three from the patient PDAC-B, as well as four samples from four other PDAC tumors, thus spanning a cohort of six patient samples ( Fig. 5c and Supplementary Figs. 10 and 11 ). We also detected significant enrichments of monocytes and T/natural killer cells in the stress-response module-high regions, though these enrichments were not as strong or as consistent as the inflammatory fibroblast enrichments.
The Cancer Genome Atlas (TCGA) project has made available the bulk transcriptomes of 183 PDAC tumors. We reasoned that if the colocalization of stress-response cancer cells and inflammatory fibroblasts reflects a functional relationship between these cells, a correlation should also be detectable at the level of entire tumors. Therefore, we computed the correlation between the expression of each identified cancer gene module and the inflammatory fibroblast gene signature. We found that only the stress-response gene module was significantly correlated with the inflammatory fibroblast signature in these datasets (Fig. 5d ). To provide further evidence for the signaling relationship between inflammatory fibroblasts and cancer cells, we performed immunofluorescence on PDAC tissue sections for IL-6, which is primarily expressed by inflammatory fibroblasts compared with other cell types in the PDAC microenvironment 51 . By immunofluorescence staining of cancer cells with KRT19, we found evidence for colocalization between the presence of IL-6 and malignant cells (Fig. 5e ). Through H&E staining of the tissue section adjacent to the section used for immunofluorescence, we confirmed that the epithelial cells throughout the tissue section indeed correspond to malignant cells (Fig. 5e, far right panel) . Taken together, these results implicate a relationship between the inflammatory fibroblasts and cancer cells expressing a stress-response gene module.
Finally, we sought to build MIA maps of other tumors types by re-analyzing publicly available data using our approach. Studying metastatic melanoma tumors, we first analyzed the scRNA-seq data from Tirosh et al. (ref. 6 ) to delineate cell types and subpopulations ( Supplementary Fig. 12a,b ). Using marker genes included in Tirosh et al., we identified three T-cell subsets 6 ( Supplementary Fig. 12b ). We then clustered the ST data of melanoma lymph node metastases from two patients analyzed in Thrane et al. 28 , and found strong correspondence between the tissue histological annotations and the ST clustering assignments ( Supplementary Fig. 12c,d, top) . Next, we generated MIA maps of the Thrane et al. ST data using populationspecific markers identified in the Tirosh et al. scRNA-seq dataset ( Supplementary Fig. 12c,d, bottom) . In both samples, we found that the stromal tissue compartment largely consisted of fibroblasts and endothelial cells. The colocalization of fibroblasts and endothelial cells was also seen in the PDAC MIA maps (Fig. 4c,d) . In both melanoma MIA maps, we also find macrophages to be spatially restricted relative to the annotated melanoma region; in the melanoma 1 ST sample the macrophages are restricted to the melanoma region periphery, and in the second ST sample the macrophages are restricted to a particular region (melanoma region 1) within the larger annotated melanoma area. In both metastatic melanoma samples, we also find that the melanoma regions have a significant depletion of CD8 + T cells, which are known be useful biomarkers for prognosis and response to therapy 52 . Collectively, these results demonstrate the utility of MIA maps for generating testable hypotheses regarding the relationships of cell populations with spatially restricted architectures.
Discussion
Here, we have presented a method for the identification and spatial mapping of distinct cell types, subpopulations and cell states within heterogeneous samples. The method begins with the characterization of cell types and subpopulations present in a tissue by scRNAseq, and, in parallel, the identification of transcriptomic regions by ST. We then take advantage of the systematic and unbiased nature of both data modalities to detect cell population enrichment across coherent transcriptomic regions using an approach we term MIA. While other methods integrate across data modalities 53, 54 , MIA provides a unique approach for integration on initial independent annotations. By applying MIA to ten PDAC ST samples, we mapped the location of distinct cell types (Fig. 2) and subpopulations ( Fig. 3 and Supplementary Fig. 7) in the tumor microenvironment, and the relationships among cell types within cancer subregions (Fig. 4) .
Given the elucidation of cancer cell states through scRNA-seq studies [5] [6] [7] 10, [13] [14] [15] [16] [17] [18] [19] [20] [21] and that extensive communication between stromal cells and cancer cells is known to influence transcriptional states in PDAC 55 , we sought to test whether we could identify unique PDAC cancer cell states and link these states to the localization of other cell types in the microenvironment. Of particular interest was the interplay between cancer cell states and fibroblast subtypes, including inflammatory fibroblasts 51, 56 . By generating MIA maps across ten ST samples, we found evidence that the stress-response cancer cell state colocalizes with the inflammatory fibroblasts ( Fig. 5) . Interestingly, the inflammatory fibroblasts have been identified as the major source of IL-6 cytokine in PDAC; this cytokine participates in a number of signaling cascades with factors encoded by our identified stress-response genes [57] [58] [59] . We found further support for this association by an analysis of the PDAC TCGA data and through immunofluorescence experiments. These results highlight the applicability of our MIA approach to reveal biological insights from systematic gene expression explorations.
Established methods for mapping transcripts (ISH, fluorescence in situ hybridization) or proteins (immunohistochemistry) are limited to a few antibodies or in situ probes, even with multiplexing. In this respect, ST has the advantage of providing an unbiased map of expressed transcripts in a given tissue section [28] [29] [30] [31] 33 . More recent spatially resolved methods can detect hundreds of RNA species at single-cell resolution 20 , but these methods do not provide transcriptome-wide measurements and consequently cannot identify all of the genes that are specifically expressed in a spatially defined tissue region. Although the sensitivity of ST may not enable the determination of specific cell type enrichment in a single ST spot, our MIA approach aims to mitigate this constraint by determining enrichment of scRNA-seq-identified cell types and cell states across clusters of spots for which gene signatures can be reliably identified. Since ST spots are clustered based on the transcriptomic data independently of tissue histology, MIA maps provide an unbiased perspective into the organization of distinct populations in local tissue niches. This allows for the inference of functional relationships between scRNAseq-defined populations based on their colocalization in space, and ultimately provides a more comprehensive characterization of cell types in their native environment than can be gained from either modality alone. As the sequencing depth achieved by this method is expected to increase, ST is well-positioned to study histologically variable tissues such as tumors, which lack ISH maps to guide cell location inference 25, 26 .
Our approach to integrating scRNA-seq and ST using MIA has important limitations. First, the ST array is about 6 × 6.5 mm 2 in size; thus, in many cases the array is not large enough to cover the entire tissue, nor does each spot achieve single-cell resolution. With the improvement of the ST technology, the method will be empowered with more spots on the array and increased sensitivity, as well as an improved protocol to further reduce the diffusion of transcripts across spots. Though tissue optimization experiments are already performed to minimize transcript diffusion 27 , these steps do not completely rule out this possibility; this is particularly true for tissues with highly variable tissue architecture, for which any one tissue permeabilization condition necessary for ST may not be necessarily optimal for all histological features captured on the ST array. Despite these limitations, ST remains very accessible to researchers as it requires only a few additional steps compared with bulk RNA-seq analysis of homogenized tissue, and, unlike other spatially resolved transcriptomic approaches 20, 21 , these additional steps do not require specialized equipment outside of standard laboratory equipment 27 .
Given the strength of scRNA-seq for the identification of cell states and subpopulations, the unique perspective offered from MIA maps can aid in assigning potential functional roles for identified cell states and subpopulations based on spatial localization (relative to the tissue or to other cell types present). In the case of tumors for which the precise composition of different tumor subclassifications is likely to vary from individual to individual, the subpopulation composition and spatial localization can be ascertained for a given patient and could in the future be of prognostic value.
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Methods
Tumor sample handling and dissociation to a single-cell suspension for scRNAseq. Three PDAC tumors were delivered in RPMI (Fisher Scientific) on ice directly from the operating room to the laboratory after clearing pathology (~2 h). Two tumor samples (PDAC-A and PDAC-B) were processed for ST and scRNA-seq in parallel: tumors were rinsed in ice-cold PBS and cut into ~4-5-mm 3 pieces from which 1-mm-thick slices were taken and set aside in ice-cold PBS. The remaining ~3-4-mm 3 pieces were embedded in optimal cutting temperature compound (OCT) and frozen in isopentane cooled with liquid N 2 . The 1-mm tissue slices were further minced with scalpels to <1 mm 3 . Tissue was collected and pelleted by centrifuging at 300g for 3 min at 4 °C. PBS was aspirated and 5 ml of 0.25% prewarmed trypsin-EDTA with 10 U µl −1 DNaseI (Roche) was added and put into a 37 °C water bath for 30 min with gentle inversion every 5 min. The resulting suspension was filtered through a 100-µm cell strainer to remove larger chunks of undigested tissue. Enzymatic digestion was quenched with the addition of FBS to a final concentration of 10%. Cells were pelleted by centrifuging the suspension at 800g for 3 min at 4 °C and washed twice with 5 ml of ice-cold PBS. After a final spin at 300g for 3 min, the cells were resuspended in PBS to a final concentration of 10,000 cells per ml. The PDAC-C tumor sample ( Supplementary Fig. 9 ) was only processed for scRNA-seq, involving enzymatic digestion as described in this section. The resulting viability was >95% as shown by trypan blue exclusion.
inDrop library preparation and scRNA-seq. From each single-cell suspension, between 6,000 and 12,000 cells were encapsulated using the inDrop platform and the reverse transcription reaction was performed as previously described 44 . Each library was prepared from aliquots consisting of 2,000-2,500 encapsulated cells. Libraries were diluted to 4 nM and paired-end sequencing was performed on an Illumina NextSeq platform. Between 139 million and 145 million pairedreads were generated for each library (estimated 2,000-2,500 encapsulated cells), corresponding to ~58,000 paired-reads per cell before computational filtering of low-quality cells.
scRNA-seq initial processing. Raw sequencing data obtained from the inDrop method were processed using a custom-built pipeline (https://github.com/flocompbio/singlecell). Briefly, the 'W1' adapter sequence of the inDrop reverse transcription primer was located in the barcode read (read 2), by comparing the 22-mer sequences starting at positions 9-12 of the read with the known W1 sequence ('GAGTGATTGCTTGTGACGCCTT'), allowing at most two mismatches. Reads for which the W1 sequence could not be located in this way were discarded. The start position of the W1 sequence was then used to infer the length of the first part of the inDrop cell barcode in each read (8-11 base pairs), as well as the start position of the second part of the inDrop cell barcode (8 base pairs). Cell barcode sequences were mapped to the known list of 384 barcode sequences for each read, allowing at most one mismatch. The resulting barcode combination was used to identify the cell from which the fragment originated. Finally, the UMI sequence was extracted, and reads with low-confidence base calls for the six bases comprising the UMI sequence (minimum Phred score less than 20) were discarded. The reads containing the messenger RNA sequence were mapped by STAR 2.5.1 with parameter '-outSAMmultNmax 1' and default settings otherwise 60 . Mapped reads were split according to their cell barcode and assigned to genes by testing for overlap with exons of protein-coding genes. Only single-cell transcriptomes with ≥1,000 UMIs, ≤20% mitochondrial transcripts and ≤30% ribosomal transcripts were kept. UMI counts were normalized by the total transcript count and scaled by the median count (transcripts per median, TPM). Expression was transformed using the Freeman-Tukey transform as described previously 37 .
KNN smoothing of scRNA-seq data. To reduce the noise inherent to scRNA-seq data 38 , we applied KNN smoothing 37 . Briefly, all single-cell expression profiles were normalized by the total transcript count and scaled by the median number of total transcripts across all cells, the Freeman-Tukey transformation was applied to all expression values and the k closest neighbors of each cell were identified using Euclidean distance. The expression profile of each cell was then combined with those of its neighbors, thus obtaining its smoothed expression profile.
Hierarchical clustering of scRNA-seq data and marker gene selection. For clustering and identification of cell types, we used a recursive clustering scheme involving data smoothing, clustering, removal of identified and repeating until all clusters are identified. The data were first smoothed using KNN smoothing 37 , normalized and scaled by the median transcript count (TPM) and transformed using the Freeman-Tukey transformation y = √x + √(x + 1), where 'x' is the TPMnormalized expression of any given gene for any given cell, and 'y' is the Freeman-Tukey transformed expression. Cells were then clustered with Ward's criterion using the most variable genes (defined as Fano factor and mean expression above mean-dependent threshold). From resulting clusters, we obtained a list of marker genes by examining genes that were differentially expressed (P < 10 −5 , two-tailed Student's t-test; effect size >0.2, Cohen's d). For each gene with P < 10 −5 , we examined for which cell type the effect size was highest and determined that gene to be specific for this cell type. While clustering the PDAC-B data, we identified a population of ductal cells with low UMI counts and high mitochondrial content. Because of these reasons, and the lack of a similar population in PDAC-A and PDAC-C, we suspected these cells to be low-quality cells that may have arisen as an artifact of the dissociation process. These cells were therefore removed from the PDAC-B dataset.
Correlation between cell types in the scRNA-seq data. To determine the similarity between cell types identified in PDAC-A and PDAC-B, the transcriptomes of all cells in each cluster were averaged (after TPM normalization and applying the Freeman-Tukey transform, see above). The top most variably expressed genes within each scRNA-seq were identified using the Fano factor (see above), and the union between these two gene sets was used to compute the Pearson's correlation coefficient between the averaged cell type profiles.
Identification of ductal subpopulations. To subcluster the ductal subpopulations, the ductal cells were first isolated from the expression matrix and smoothed using KNN smoothing 37 with k = 64. Cells were then clustered with hierarchical clustering using the top variably expressed genes (see section 'Hierarchical clustering of scRNA-seq data and marker gene selection'). To annotate subpopulations, differentially expressed genes between each subpopulation were identified using a two-tailed Student's t-test (P < 10 −5 ). The top 200 differentially expressed genes for each subpopulation were used for the heatmap visualization shown in Fig. 3c,d .
Dimensionality reduction (PCA and t-SNE). Dimensionality reduction methods
were performed on the Freeman-Tukey-transformed data (after normalizing UMI counts to the median as described in 'scRNA-seq initial processing') using variable genes (defined as Fano factor and mean expression above mean-dependent threshold). t-distributed stochastic neighbor embedding (t-SNE) was performed using the following parameters: perplexity = 30 and initial dimension = number of principal components explaining >90% of the variance 61 .
CNV analysis. To estimate CNV profiles, PDAC-A, PDAC-B and PDAC-C scRNA-seq gene expression matrices were smoothed with KNN smoothing 37 , using k = 10. Next, genes were sorted based on their chromosomal location and a moving average of gene expression was calculated using a window size of 0.1 multiplied by the number of genes of each chromosome. The expression was then centered to zero by subtracting the mean. A subset of 200 randomly selected ductal cells was removed as a negative control for the analysis, leaving all remaining cells as the background.
Tissue preparation, cryosectioning, fixation, staining and brightfield imaging for ST. Patients at New York University (NYU) Langone Health consented preoperatively to participate in the study. PDAC tissue was gently washed with cold PBS and cut into 4-5-mm 3 pieces. From each piece of fresh tissue, a 1-mmthick portion of tissue was removed for preparing a single-cell suspension (see above). The surface from which the 1-mm-thick tissue for scRNA-seq was cut was then placed cut side down into a plastic mold (such that the side of the tissue cut for preparing the single-cell suspension is then cryosectioned for ST). The OCTfilled mold was then snap frozen in chilled isopentane. Cryosections were cut at 10-µm thickness, mounted onto the ST arrays and stored at −80 °C until use. For processing, the tissue was first warmed to 37 °C for 1 min and fixed for 10 min with 3.6% formaldehyde in PBS. Next, the tissue was dehydrated with isopropanol for 1 min followed by staining with H&E. Slides were mounted in 80% glycerol and brightfield images were taken on a Leica SCN400 F whole-slide scanner at 40× resolution.
ST barcoded microarray slide information. Library preparation slides used were purchased from the Spatial Transcriptomics team (https://www. spatialtranscriptomics.com; lot 10002 for PDAC-A ST, lot 10003 for PDAC-B ST and lot 10010 for PDAC-D, -E, -F, -G ST). Each of the spots printed onto the array is 100 µm in diameter and 200 µm from center to center, covering an area of 6.1 × 6.5 mm 2 . Spots are printed with approximately 2 × 10 8 oligonucleotides containing an 18-mer spatial barcode, a randomized 7-mer UMI and a poly-20TVN transcript capture region 27 (Fig. 1a ).
On-slide tissue permeabilization, cDNA synthesis and probe release. After brightfield imaging, the ST slide was prewarmed to 42 °C and attached to a microarray slide module (Grace Biolabs). The sections were prepermeabilized with 0.2 mg ml −1 BSA and 200 units of collagenase diluted in HBSS buffer for 20 min at 37 °C and washed with 100 µl of 0.1× SSC buffer. Tissue was permeabilized with 0.1% pepsin in HCl for 4 min at 42 °C and washed with 100 µl of 0.1× SSC buffer. Reverse transcription was carried out overnight (~18-20 h) at 42 °C by incubating permeabilized tissue with 75 µl of cDNA synthesis mix containing 1× First strand buffer (Invitrogen), 5 mM dithiothreitol, 0.5 mM of each dNTP, 0.2 µg µl −1 BSA, 50 ng µl −1 Actinomycin D, 1% dimethylsulfoxide, 20 U µl −1 Superscript III (Invitrogen) and 2 U µl −1 RNaseOUT (Invitrogen). Tissue was then digested away from the slide by incubating the tissue with 1% 2-mercaptoethanol in RLT buffer (Qiagen) for 1 h at 56 °C with interval shaking, followed by digestion with
